Effects of a health program comprising reassurance, diet management, probiotics administration and regular exercise on symptoms and quality of life in patients with irritable bowel syndrome

Gastroenterology Insights

Volumn 2, Issue 1, 2010, Pages 21-26

  El Salhy, Magdy ^a,b   Lillebo, Elli ^a   Reinemo, Astrid ^a   Salmelid, Lillian ^a   Hausken, Trygve ^a  

^a Stord Helse Fonna Hospital   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Irritable bowel syndrome; Probiotics; Quality of life; Reassurance; Symptom score

Indexed keywords

PROBIOTIC AGENT;

ADULT; AEROBIC EXERCISE; ARTICLE; CONSTIPATION; DIARRHEA; DIET THERAPY; FEMALE; HEALTH PROGRAM; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT EDUCATION; PATIENT INFORMATION; QUALITY OF LIFE; QUESTIONNAIRE; REASSURANCE;

EID: 79952605662     PISSN: None     EISSN: 20367422     Source Type: Journal    
DOI: 10.4081/gi.2010.e6     Document Type: Article

References (58)

1. Thompson WG. A world view of IBS. In Camilleri M, Spiller R eds: Irritable bowel syndrome: Diagnosis and treatment. Philadelphia and London: Saunders; 2002, pp 17-26.
2. Agreus L, Svarsudd K, Nygren O, Tibblin G. Irritable bowel syndrome and dyspepsia in general population: overlap and lack of stability over time. Gastroenterology 1995; 109:671-80.
3. Thompson WG, Haeton KW Functional bowel disorders in apparently healthy people. Gastorenterology 1980;79:283-8.
4. Kennedy TM, Jones RH, Hungin AP, et. Irritable bowel syndrome, gastrooesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut 1998;43:770-4.
5. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-80.
6. Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995;109:1736-41.
7. Hugin AP, Whonwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Alment Pharmacol Ther 2003;17:643-50.
8. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992; 304:87-90.
9. Bordie AK. Functional disorders of the colon. J Indian Med Assoc 1972;58:451-6.
10. O'Keefe EA, Talley NJ, Zinsmeister AR, Jacobsen SJ. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Biol Sci Med Sci 1995;50:M184-M189.
11. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991;100: :998-1005.
12. Wilson S, Roberts L, Roalfe A, Bridge P, Sukhdev S. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 2004;54:495-502.
13. Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1983;1:632-4.
14. Spiegel BM. The burden of IBS: looking at metrics. Curr Gastroenterol Rep 2009;11: 265-9.
15. Whitehead WE, Burnett CK, Cook EW III, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dig Sci 1996;41: 2248-53.
16. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health related quality of life. Gastroenterology 2000;11:654-60.
17. Huerta-Icelo I, Hinojosa C, Santa Maria A, Schmulson M. Diferencias en la calidad de vida (CV) entre pacientes con sindrome de Intestino irritable (SII) y la poblacon mexicana evaluadas mediante el SF-36. Rev Mex Gastroenterol 2001;66:145-6.
18. Schmulson M, Robles G, Kershenobich D, Lopez-Ridaura R, Hinojosa C, Duarte, et al. Los pacientes con trastornos funcionales digestivos (TFD) tienen major compromiso de la calidad de vida (CV) evaluadas por el SF-36 comparados con pacientes con hepatitis C y pancreatitis cronica. Rev Mex Gastroenterol 2000;65 (Suppl-Resumenes):50-1.
19. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009;43:541-50.
20. Schuster MM. Defining and diagnosing irritable bowel syndrome. Am J Manag Care 2001;7:S246-251.
21. National ambulatory Medical Care Survey. National Center for Health Statistics: NAMCS Description. Available at: httpy/www.cdc.gov/nchs/about/major/ahcd/namcsdes.htm.
22. Mitchel CM, Drossman DA. Survey of AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987;92:1282-4.
23. American Gastroenterological association. The Burden of Gastrointestinal Diseases, Bethesda, MD, 2001.
24. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11.
25. Spanier JS, Howden CW, Jones MP. A systematic review of alternative therapies in irritable bowel syndrome. Arch Intern Med 2003;163:265-74.
26. Pasricha PJ. Desperately seeking serotonin: a commentary on the withdrawal of tegaserod and the state of functional and motility disorders. Gastroenterology 2007; 132:2287-90.
27. Wald A, Rakel D. Behavioral and complementary approaches for the treatment of irritable bowel syndrome. Nutr Clin Pract 2008;23:284-92.
28. Schmulson MJ, Ortiz-Garrido OM, Hinojosa C, Arcila D. A single session of reassurance can acutely improve the self-perception of impairment in patients with IBS. J Psychosom Res 2006;6:461-7.
29. Clowell LJ, Prather CM, Philips SF, Zinsmeister AR. Effects of an irritable bowel syndrome educational class on health-promoting behaviors and symptoms. Am J Gastroenterol 1998;93:901-5.
30. Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc 2009;109:1204-14.
31. Singh N, Makharia GK, Joshi YK. Dietary survey and total dietary intake in patients with irritable bowel syndrome attending a tertiary referral hospital. Indian J Gastroenterol 2008; 27:66-70.
32. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009;104:1033-49.
33. Speller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Alment Pharmacol Ther 2008;28:385-96.
34. Levy RL, Linde JA, Feld KA, Crowell MD, Jeffery RW The association pf gastrointestinal symptoms with weight diet and exercise in weight-loss program participants. Clin Gastroenterol Hepatol 2005; 2:992-6.
35. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorder. Gastroenterology 2006;130:1480-91.
36. Roalfe AK, Roberts LM, Wilson S. Evaluation of the Birmingham IBS symptom questionnaire. BMC Gastroenterol 2008;8:30-6.
37. Bensoussan A, Chang SW, Menzies RG, Talley NJ. Application of the general status questionnaire SF36 to patients with gastrointestinal dysfunction: initial validation and validation as a measure of change. Aust N Z J Public Health 2001;25:71-7.
38. McCallum J. The SF-36 in an Australian sample: validating a new, generic health status measure. Aust J Public Health 1995;19:160-6.
39. Garrat AM, Ruta DA, Absalla MI, et al. The SF-36 health survey questionnaire: an outcome measure suitable for use within the NHS? Br Med J 1993;306:1440-4.
40. McHorney CA, Ware JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31:247-63.
41. McHorney CA, Ware JE, Lu JFR, Sher-bourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:44-66.
42. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999-1007.
43. Whitehead WE, Bosmajian L, Zonderman AB, Costa PT, Shuster MM. Symptoms of psychological distress associated with irritable syndrome. Comparasion of community and medical clinical samples. Gastroenterolog 1988;95:709-14.
44. Fowlie S, Eastwood MA, Ford MJ. Irritable bowel syndrome: the influence of psychological factors on the symptom complex. J Psychosom Res 1992;36:169-73.
45. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence characteristics and referral. Gut 2000;46:78-82.
46. Simons-Morton DG, Mullen PD, Mains DA, et al. Characteristics of controlled studies of patient education and counseling for preventive health behaviors. Patient Educ Couns 1992;19:175-204.
47. Mullen PD, Mains DA, Velez R. A meta analysis of controlled trials of cardiac patient education. Patient Educ Couns 1992;19:142-62.
48. Soares RL, Figueiredo MN, Maneschy CP, et al. Correlation between symptoms of the irritable bowel syndrome and the response to the food extracts skin prick test. Braz J Med Biol Res 2004;37:659-62.
49. Austin GL, Dalton CB, Hu Y, et al. A very low-carbohydrate diet improves symptoms and quality of life in diarrhoea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2009;7:706-8.
50. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et. al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33.
51. Spiller RC. Problems and challenges in the design of irritable bowel syndrome trials: experience from published trials. Am J Med 1999;107:915-75.
52. Jaiwala J, Imperiale TF, Kroenke K. Pharmacological treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136-47.
53. Thompson WG. Placebos: a review of the placebo response. Am J Gastroenterol 2000;95:1637-43.
54. Camilleri M, Talley NJ. Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. Neurogastroenterol Motil 2004;16:135-42.
55. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005;17:332-40.
56. Ilnyckyj A, Shanahan F, Anton PA, et al. Quantification of the placebo response in ulcerative colitis. Gastroenterolgy 1997; 112:1854-8.
57. Traut EF, Passarelli EW Placebos in the treatment of rheumatoid arthritis and other rheumatic conditions. Ann Rheum Dis 1957;16:18-22.
58. Spiegel D. Placebos in practice. BMJ 2004;329:927-8.